Lantheus expands radiopharmaceutical oncology pipeline via strategic agreements with Perspective Therapeutics.
Lantheus Holdings, Inc. announced it has entered into multiple strategic agreements with Perspective Therapeutics, Inc. , a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body
Under the agreements, 1) Lantheus obtains an option to exclusively license Perspective’s Pb212-VMT-?-NET, a clinical stage alpha therapy developed for the treatment of neuroendocrine tumors, and an option to co-develop certain early stage therapeutic candidates targeting prostate cancer using Perspective’s innovative lead platform technology, for an aggregate upfront payment of $28 million in cash; 2) Lantheus has agreed to purchase up to 19.9% of Perspective’s outstanding shares of common stock for up to approximately $33 million, subject to completion of a qualified third party financing transaction and certain other closing conditions; and 3) Perspective intends to acquire the assets and associated lease of Lantheus’ radiopharmaceutical manufacturing facility in Somerset, New Jersey for an undisclosed price.